☆ 4.7 Editorial Material

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors

JOURNAL OF CLINICAL ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Yulei Zhao et al.

Summary: Resistance to KRAS(G12C) inhibitors demonstrates a heterogeneous pattern with multiple subclonal events emerging during treatment. Co-targeting of ERK signaling intermediates can enhance the antiproliferative effect of G12C inhibitor treatment in models with acquired RAS or BRAF mutations.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS

Chuanchuan Li et al.

Summary: This study reveals that RGS3 enhances the GTPase activity of both mutant and wild-type KRAS proteins, leading to the inactivation of KRAS and explaining its vulnerability to emerging clinically effective therapies.

SCIENCE (2021)

Add to Collection

Article Oncology

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

Takamasa Koga et al.

Summary: The study developed in vitro models of KRAS G12C cancer resistant to sotorasib and adagrasib, and found that most clones harbored secondary KRAS mutations which showed differential sensitivity to the inhibitors. Sequential use of sotorasib and adagrasib may be considered in some cases, while a combination of BI-3406 and trametinib could be an effective strategy to overcome resistance caused by secondary Y96D and Y96S mutations.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation

Noritaka Tanaka et al.

Summary: This study described a patient with KRAS(G12C) non-small cell lung cancer who developed polyclonal acquired resistance to MRTX849 treatment. The research identified 10 heterogeneous resistance alterations that converged to reactivate the RAS-MAPK signaling pathway. Additionally, a novel KRAS(Y96D) mutation affecting key protein-drug interactions and driving resistance was discovered.

CANCER DISCOVERY (2021)

Add to Collection

Meeting Abstract Oncology

KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

J. Weiss et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Acquired Resistance to KRASG12C Inhibition in Cancer

M. M. Awad et al.

Summary: A study of 38 patients with KRAS(G12C)-mutant cancers treated with adagrasib revealed diverse mechanisms of acquired resistance in 45% of them, including various mutations and bypass mechanisms. New therapeutic strategies are needed to overcome this drug resistance.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition

Meagan B. Ryan et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin et al.

CANCER DISCOVERY (2020)

Add to Collection

Article Multidisciplinary Sciences

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

Jenny Y. Xue et al.

NATURE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients

Dongsung Kim et al.

CELL (2020)

Add to Collection

Article Oncology

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Yuta Adachi et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon et al.

NATURE (2019)

Add to Collection

Article Multidisciplinary Sciences

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Piro Lito et al.

SCIENCE (2016)

Add to Collection

Article Multidisciplinary Sciences

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Jonathan M. Ostrem et al.

NATURE (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.